P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

Hemasphere · 2022 · PMC9430776

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Prevalence of atrial fibrillation remained ≤5% and hypertension remained stable with ZANU, each with a lower prevalence at all intervals vs an increasing trend seen with IBR.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.